Home › Compare › CYFWY vs ABBV
CYFWY yields 12.38% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, CYFWY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYFWY + ABBV for your $10,000?
Cyfrowy Polsat S.A. provides digital satellite platform and terrestrial television (TV), and telecommunication services in Poland. The company offers satellite and Internet pay television, mobile and fixed-line telephony, mobile and fixed-line broadband Internet access, wholesale, and TV broadcasting and production services, as well as online content, news, and video sharing services. It offers approximately 150 TV channels, including terrestrial, general entertainment, sports and e-sports, music, lifestyle, news/information, children's, education, and movie channels; and over the top services, such as Cyfrowy Polsat GO, VOD/PPV, online video and music, catch-up TV, and multiroom HD services. In addition, the company provides database of legal video content and live broadcasts; online TV channels; live coverages of sports events; and feature films, and TV series and programs. Further, it offers telecommunications, software, retail, radio and TV, media, call center and premium rate, technical, advertising, Web portals, monetary intermediation, sponsorship, broadcasting and signal transmission, premises and facilities leasing, and other financial services; produces broadcasting, television, and electronic equipment; produces, leases, and sells set-top boxes; and sells licenses, sublicenses, and property rights, as well as STB hard disk drives, antennas, Internet modems, tablets, laptops, routers, TV sets, accessories, and other devices. The company was formerly known as Polsat Cyfrowy S.A. and changed its name to Cyfrowy Polsat S.A. in 2004. Cyfrowy Polsat S.A. was incorporated in 1996 and is headquartered in Warsaw, Poland.
Full CYFWY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.